ADRB2 and neoplasm: Notably, β-AR blockers decreased the percentage of HSCs and MSCs in tumor sites with a stronger activity of SR59230A, demonstrating a direct involvement of β3-ARs in maintaining stemness in the TME (Figure 2e,f).